Patient Release Program, 24745-24746 [2017-11027]

Download as PDF 24745 sradovich on DSK3GMQ082PROD with NOTICES Federal Register / Vol. 82, No. 102 / Tuesday, May 30, 2017 / Notices not filing electronically and requesting authorization to continue to submit documents in paper format. Such filings must be submitted by: (1) First class mail addressed to the Office of the Secretary of the Commission, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001, Attention: Rulemaking and Adjudications Staff; or (2) courier, express mail, or expedited delivery service to the Office of the Secretary, 11555 Rockville Pike, Rockville, Maryland 20852, Attention: Rulemaking and Adjudications Staff. Participants filing adjudicatory documents in this manner are responsible for serving the document on all other participants. Filing is considered complete by first-class mail as of the time of deposit in the mail, or by courier, express mail, or expedited delivery service upon depositing the document with the provider of the service. A presiding officer, having granted an exemption request from using E-Filing, may require a participant or party to use E-Filing if the presiding officer subsequently determines that the reason for granting the exemption from use of E-Filing no longer exists. Documents submitted in adjudicatory proceedings will appear in the NRC’s electronic hearing docket which is available to the public at https:// adams.nrc.gov/ehd, unless excluded pursuant to an order of the Commission or the presiding officer. If you do not have an NRC-issued digital ID certificate as described above, click cancel when the link requests certificates and you will be automatically directed to the NRC’s electronic hearing dockets where you will be able to access any publicly available documents in a particular hearing docket. Participants are requested not to include personal privacy information, such as social security numbers, home addresses, or personal phone numbers in their filings, unless an NRC regulation or other law requires submission of such information. For example, in some instances, individuals provide home addresses in order to demonstrate proximity to a facility or site. With respect to copyrighted works, except for limited excerpts that serve the purpose of the adjudicatory filings and would constitute a Fair Use application, participants are requested not to include copyrighted materials in their submission. For further details with respect to this action, see the application for license amendment dated May 19, 2017 (ADAMS Accession No. ML17139C739). Attorney for licensee: Donald P. Ferraro, Assistant General Counsel, Exelon Generation Company, LLC, 200 VerDate Sep<11>2014 19:59 May 26, 2017 Jkt 241001 Exelon Way, Suite 305, Kennett Square, PA 19348. Dated at Rockville, Maryland, this 24th day of May 2017. For the Nuclear Regulatory Commission. James G. Danna, Chief, Plant Licensing Branch I–1, Division of Operating Reactor Licensing, Office of Nuclear Reactor Regulation. [FR Doc. 2017–11039 Filed 5–26–17; 8:45 am] SUPPLEMENTARY INFORMATION section of this document. FOR FURTHER INFORMATION CONTACT: Donna-Beth Howe, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001; telephone: 301–415–7848; email: DonnaBeth.Howe@nrc.gov. SUPPLEMENTARY INFORMATION: BILLING CODE 7590–01–P I. Obtaining Information and Submitting Comments NUCLEAR REGULATORY COMMISSION A. Obtaining Information Please refer to Docket ID NRC–2017– 0094 when contacting the NRC about the availability of information for this action. You may obtain publiclyavailable information related to this action by any of the following methods: • Federal Rulemaking Web site: Go to https://www.regulations.gov and search for Docket ID NRC–2017–0094. • NRC’s Agencywide Documents Access and Management System (ADAMS): You may obtain publiclyavailable documents online in the ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/ adams.html. To begin the search, select ‘‘ADAMS Public Documents’’ and then select ‘‘Begin Web-based ADAMS Search.’’ For problems with ADAMS, please contact the NRC’s Public Document Room (PDR) reference staff at 1–800–397–4209, 301–415–4737, or by email to pdr.resource@nrc.gov. The ADAMS accession number for each document referenced (if it is available in ADAMS) is provided the first time that it is mentioned in the SUPPLEMENTARY INFORMATION section. • NRC’s PDR: You may examine and purchase copies of public documents at the NRC’s PDR, Room O1–F21, One White Flint North, 11555 Rockville Pike, Rockville, Maryland 20852. [NRC–2017–0094] Patient Release Program Nuclear Regulatory Commission. ACTION: Extension of comment period. AGENCY: On April 11, 2017, the U.S. Nuclear Regulatory Commission (NRC) solicited comments on its patient release program. The public comment period was originally scheduled to close on June 12, 2017. The NRC has decided to extend the public comment period to allow more time for members of the public to develop and submit their comments. SUMMARY: The due date of comments requested in the document published on April 11, 2017 (82 FR 17465), is extended. Comments should be filed no later than June 27, 2017. Comments received after this date will be considered, if it is practical to do so, but the NRC is able to ensure consideration only for comments received on or before this date. ADDRESSES: You may submit comments by any of the following methods (unless this document describes a different method for submitting comments on a specific subject): • Federal Rulemaking Web site: Go to https://www.regulations.gov and search for Docket ID NRC–2017–0094. Address questions about NRC dockets to Carol Gallagher; telephone: 301–415–3463; email: Carol.Gallagher@nrc.gov. For technical questions, contact the individual listed in the FOR FURTHER INFORMATION CONTACT section of this document. • Mail comments to: Cindy Bladey, Office of Administration, Mail Stop: TWFN–8–D36M, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001. For additional direction on obtaining information and submitting comments, see ‘‘Obtaining Information and Submitting Comments’’ in the DATES: PO 00000 Frm 00087 Fmt 4703 Sfmt 4703 B. Submitting Comments Please include Docket ID NRC–2017– 0094 in your submission. The NRC cautions you not to include identifying or contact information that you do not want to be publicly disclosed in your comment submission. The NRC posts all comment submissions at https:// www.regulations.gov as well as entering the comment submissions into ADAMS. The NRC does not routinely edit comment submissions to remove identifying or contact information. If you are requesting or aggregating comments from other persons for submission to the NRC, then you should inform those persons not to include identifying or contact information that they do not want to be publicly E:\FR\FM\30MYN1.SGM 30MYN1 24746 Federal Register / Vol. 82, No. 102 / Tuesday, May 30, 2017 / Notices disclosed in their comment submission. Your request should state that the NRC does not routinely edit comment submissions to remove such information before making the comment submissions available to the public or entering the comment submissions into ADAMS. II. Discussion On April 11, 2017, the NRC solicited comments on its patient release program. The purpose of requesting information from the general public on its patient release program was to receive input from the public on whether additional or alternate criteria are needed and whether to clarify NRC’s current patient release criteria. The information collected will be used to determine whether significant regulatory changes to NRC’s patient release program are warranted. The public comment period was originally scheduled to close on June 12, 2017. The NRC has decided to extend the public comment period on this document until June 27, 2017, to allow more time for members of the public to submit their comments. Dated at Rockville, Maryland, this 24th day of May 2017. For the Nuclear Regulatory Commission. Daniel S. Collins, Director, Division of Material Safety, State, Tribal and Rulemaking Programs, Office of Nuclear Material Safety and Safeguards. [FR Doc. 2017–11027 Filed 5–26–17; 8:45 am] BILLING CODE 7590–01–P NUCLEAR REGULATORY COMMISSION Advisory Committee on Reactor Safeguards (ACRS) Meeting of the ACRS Subcommittee on APR1400; Notice of Meeting sradovich on DSK3GMQ082PROD with NOTICES The ACRS Subcommittee on APR1400 will hold a meeting on June 5, 2017, at 11545 Rockville Pike, Room T–2B1, Rockville, Maryland 20852. The meeting will be open to public attendance with the exception of portions that may be closed to protect information that is proprietary pursuant to 5 U.S.C. 552b(c)(4). The agenda for the subject meeting shall be as follows: Monday, June 5, 2017—8:30 a.m. Until 5:00 p.m. The Subcommittee will review the APR1400 design control document— Chapter 3, ‘‘Design of Structures, Systems, Components, and Equipment;’’ and associated safety evaluation report. The Subcommittee will hear presentations by and hold discussions VerDate Sep<11>2014 19:59 May 26, 2017 Jkt 241001 with the NRC staff and Korea Hydro & Nuclear Power Company regarding this matter. The Subcommittee will gather information, analyze relevant issues and facts, and formulate proposed positions and actions, as appropriate, for deliberation by the Full Committee. Members of the public desiring to provide oral statements and/or written comments should notify the Designated Federal Official (DFO), Christopher Brown (Telephone 301–415–7111 or Email: Christopher.Brown@nrc.gov) five days prior to the meeting, if possible, so that appropriate arrangements can be made. Thirty-five hard copies of each presentation or handout should be provided to the DFO thirty minutes before the meeting. In addition, one electronic copy of each presentation should be emailed to the DFO one day before the meeting. If an electronic copy cannot be provided within this timeframe, presenters should provide the DFO with a CD containing each presentation at least thirty minutes before the meeting. Electronic recordings will be permitted only during those portions of the meeting that are open to the public. Detailed procedures for the conduct of and participation in ACRS meetings were published in the Federal Register on October 17, 2016, (81 FR 71543). Detailed meeting agendas and meeting transcripts are available on the NRC Web site at https://www.nrc.gov/readingrm/doc-collections/acrs. Information regarding topics to be discussed, changes to the agenda, whether the meeting has been canceled or rescheduled, and the time allotted to present oral statements can be obtained from the Web site cited above or by contacting the identified DFO. Moreover, in view of the possibility that the schedule for ACRS meetings may be adjusted by the Chairman as necessary to facilitate the conduct of the meeting, persons planning to attend should check with these references if such rescheduling would result in a major inconvenience. If attending this meeting, please enter through the One White Flint North building, 11555 Rockville Pike, Rockville, Maryland 20852. After registering with Security, please contact Mr. Theron Brown (Telephone 240– 888–9835) to be escorted to the meeting room. Dated: May 19, 2017. Mark L. Banks, Chief, Technical Support Branch, Advisory Committee on Reactor Safeguards. [FR Doc. 2017–11075 Filed 5–26–17; 8:45 am] BILLING CODE 7590–01–P PO 00000 Frm 00088 Fmt 4703 Sfmt 4703 NUCLEAR REGULATORY COMMISSION [Docket Nos. 50–220 and 50–410; NRC– 2017–0129] Exelon Generation Company, LLC; Nine Mile Point Nuclear Station, Units 1 and 2 Nuclear Regulatory Commission. ACTION: License amendment application; opportunity to comment, request a hearing, and to petition for leave to intervene. AGENCY: The U.S. Nuclear Regulatory Commission (NRC) is considering issuance of an amendment to Renewed Facility Operating License Nos. DPR–63 and NPF–69, issued to Exelon Generation Company, LLC, for operation of the Nine Mile Point Nuclear Station, Units 1 and 2, respectively. The proposed amendments would change the Emergency Action Level (EAL) HU1.5. SUMMARY: Submit comments by June 29, 2017. A request for a hearing or petition for leave to intervene must be filed by July 31, 2017. ADDRESSES: Please refer to Docket ID NRC–2017–0129 when contacting the NRC about the availability of information regarding this document. You may obtain publicly-available information related to this document using any of the following methods: • Federal Rulemaking Web site: Go to https://www.regulations.gov and search for Docket ID NRC–2017–0129. Address questions about NRC dockets to Carol Gallagher; telephone: 301–415–3463; email: Carol.Gallagher@nrc.gov. For technical questions, contact the individual listed in the FOR FURTHER INFORMATION CONTACT section of this document. • NRC’s Agencywide Documents Access and Management System (ADAMS): You may obtain publiclyavailable documents online in the ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/ adams.html. To begin the search, select ‘‘ADAMS Public Documents’’ and then select ‘‘Begin Web-based ADAMS Search.’’ For problems with ADAMS, please contact the NRC’s Public Document Room (PDR) reference staff at 1–800–397–4209, 301–415–4737, or by email to pdr.resource@nrc.gov. The ADAMS accession number for each document referenced (if it is available in ADAMS) is provided the first time that a document is referenced. • NRC’s PDR: You may examine and purchase copies of public documents at DATES: E:\FR\FM\30MYN1.SGM 30MYN1

Agencies

[Federal Register Volume 82, Number 102 (Tuesday, May 30, 2017)]
[Notices]
[Pages 24745-24746]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-11027]


-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[NRC-2017-0094]


Patient Release Program

AGENCY: Nuclear Regulatory Commission.

ACTION: Extension of comment period.

-----------------------------------------------------------------------

SUMMARY: On April 11, 2017, the U.S. Nuclear Regulatory Commission 
(NRC) solicited comments on its patient release program. The public 
comment period was originally scheduled to close on June 12, 2017. The 
NRC has decided to extend the public comment period to allow more time 
for members of the public to develop and submit their comments.

DATES: The due date of comments requested in the document published on 
April 11, 2017 (82 FR 17465), is extended. Comments should be filed no 
later than June 27, 2017. Comments received after this date will be 
considered, if it is practical to do so, but the NRC is able to ensure 
consideration only for comments received on or before this date.

ADDRESSES: You may submit comments by any of the following methods 
(unless this document describes a different method for submitting 
comments on a specific subject):
     Federal Rulemaking Web site: Go to https://www.regulations.gov and search for Docket ID NRC-2017-0094. Address 
questions about NRC dockets to Carol Gallagher; telephone: 301-415-
3463; email: Carol.Gallagher@nrc.gov. For technical questions, contact 
the individual listed in the FOR FURTHER INFORMATION CONTACT section of 
this document.
     Mail comments to: Cindy Bladey, Office of Administration, 
Mail Stop: TWFN-8-D36M, U.S. Nuclear Regulatory Commission, Washington, 
DC 20555-0001.
    For additional direction on obtaining information and submitting 
comments, see ``Obtaining Information and Submitting Comments'' in the 
SUPPLEMENTARY INFORMATION section of this document.

FOR FURTHER INFORMATION CONTACT: Donna-Beth Howe, Office of Nuclear 
Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, 
Washington, DC 20555-0001; telephone: 301-415-7848; email: Donna-Beth.Howe@nrc.gov.

SUPPLEMENTARY INFORMATION: 

I. Obtaining Information and Submitting Comments

A. Obtaining Information

    Please refer to Docket ID NRC-2017-0094 when contacting the NRC 
about the availability of information for this action. You may obtain 
publicly-available information related to this action by any of the 
following methods:
     Federal Rulemaking Web site: Go to https://www.regulations.gov and search for Docket ID NRC-2017-0094.
     NRC's Agencywide Documents Access and Management System 
(ADAMS): You may obtain publicly-available documents online in the 
ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/adams.html. To begin the search, select ``ADAMS Public Documents'' and 
then select ``Begin Web-based ADAMS Search.'' For problems with ADAMS, 
please contact the NRC's Public Document Room (PDR) reference staff at 
1-800-397-4209, 301-415-4737, or by email to pdr.resource@nrc.gov. The 
ADAMS accession number for each document referenced (if it is available 
in ADAMS) is provided the first time that it is mentioned in the 
SUPPLEMENTARY INFORMATION section.
     NRC's PDR: You may examine and purchase copies of public 
documents at the NRC's PDR, Room O1-F21, One White Flint North, 11555 
Rockville Pike, Rockville, Maryland 20852.

B. Submitting Comments

    Please include Docket ID NRC-2017-0094 in your submission.
    The NRC cautions you not to include identifying or contact 
information that you do not want to be publicly disclosed in your 
comment submission. The NRC posts all comment submissions at https://www.regulations.gov as well as entering the comment submissions into 
ADAMS. The NRC does not routinely edit comment submissions to remove 
identifying or contact information.
    If you are requesting or aggregating comments from other persons 
for submission to the NRC, then you should inform those persons not to 
include identifying or contact information that they do not want to be 
publicly

[[Page 24746]]

disclosed in their comment submission. Your request should state that 
the NRC does not routinely edit comment submissions to remove such 
information before making the comment submissions available to the 
public or entering the comment submissions into ADAMS.

II. Discussion

    On April 11, 2017, the NRC solicited comments on its patient 
release program. The purpose of requesting information from the general 
public on its patient release program was to receive input from the 
public on whether additional or alternate criteria are needed and 
whether to clarify NRC's current patient release criteria. The 
information collected will be used to determine whether significant 
regulatory changes to NRC's patient release program are warranted. The 
public comment period was originally scheduled to close on June 12, 
2017. The NRC has decided to extend the public comment period on this 
document until June 27, 2017, to allow more time for members of the 
public to submit their comments.

    Dated at Rockville, Maryland, this 24th day of May 2017.

    For the Nuclear Regulatory Commission.

Daniel S. Collins,
 Director, Division of Material Safety, State, Tribal and Rulemaking 
Programs, Office of Nuclear Material Safety and Safeguards.
[FR Doc. 2017-11027 Filed 5-26-17; 8:45 am]
 BILLING CODE 7590-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.